- Seasoned medical technology leader to drive global expansion
and innovation in AI-driven cancer screening
SEOUL,
South Korea, July 9, 2024
/PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of
AI-powered solutions for cancer diagnostics and therapeutics, today
announced the appointment of Teri
Thomas as Chief Business Officer (CBO) of its Cancer
Screening Group, effective July 1.
While taking on this additional role, Thomas will continue serving
as CEO of Volpara Health Technologies, which Lunit acquired in
May 2024.
Thomas, an American based in New
Zealand, brings over 25 years of executive management
experience in healthcare IT to her new role. Her expertise spans
strategy, operations, global sales, marketing leadership, with a
deep understanding of the US healthcare market. Thomas's career
includes a notable 20-year tenure at Epic, a global healthcare
systems provider, where she played a pivotal role in the company's
growth from under 100 employees to over 10,000.
As a registered nurse with a Master of Science degree, Thomas
offers a unique perspective on the intersection of IT, clinician
workflow, and patient experience. Her background includes executive
roles at population health firm Orion Health and leading IT
innovation at the University of North
Carolina Health Care.
In her expanded role, Thomas will spearhead sales and marketing
efforts for both Lunit and Volpara Health. She will focus on
expanding Lunit's business in the US and EMEA (Europe, Middle
East and Africa) markets in
2024, followed by further territorial expansion from 2025
onward.
"We are thrilled to welcome Teri
Thomas to our leadership team," said Brandon Suh, CEO of Lunit. "Her extensive
experience in healthcare IT and proven track record of driving
growth will be invaluable as we continue to expand the reach of our
cancer screening technologies globally."
Thomas expressed her enthusiasm for the new role: "I'm excited
to join Lunit and lead the Cancer Screening Group. Our combined
expertise in AI and breast health presents a unique, holistic AI
suite to make a significant impact on early cancer detection and
ultimately save lives."
The strategic acquisition of Volpara by Lunit in May 2024 has created a powerhouse in AI-driven
cancer care. This merger combines Lunit's AI-powered cancer
screening solutions with Volpara's established market presence in
breast health, positioning the unified company at the forefront of
AI-driven cancer detection and personalized cancer care
solutions.
Thomas's appointment comes at a time of strong financial
performance for Volpara. The company recently reported a robust 30%
year-over-year increase in revenue for the first half of the fiscal
year. Additionally, Volpara achieved a net cash flow positive
position marking a significant turnaround from a net outflow during
the same period last year, representing a 196% improvement
(excluding acquisition-related costs).
About Lunit
Founded in 2013, Lunit is a medical AI company on a mission to
conquer cancer. We harness AI-powered medical image analytics and
AI biomarkers to ensure accurate diagnosis and optimal treatment
for each cancer patient. Our FDA-cleared Lunit INSIGHT suite for
cancer screening serves over 3,000 hospitals and medical
institutions across 40+ countries.
Our clinical findings are featured in top journals, including
the Journal of Clinical Oncology and the Lancet Digital Health, and
presented at global conferences such as the ASCO and RSNA.
In 2024, Lunit acquired Volpara Health Technologies, setting the
stage for unparalleled synergy and accuracy, particularly in breast
health and screening technologies.
Headquartered in Seoul, South
Korea, with a network of offices worldwide, Lunit leads the
global fight against cancer. Discover more at lunit.io
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lunit-appoints-volpara-ceo-teri-thomas-as-chief-business-officer-of-cancer-screening-group-302192301.html
SOURCE Lunit